With the U.S. Food & Drug Administration's (FDA) emergency use authorizations and subsequent recommendations from the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices, both the Pfizer-BioNTech and Moderna COVID-19 vaccines are now being distributed in limited quantities across the U.S. - even making their way to healthcare workers who received their first doses in mid-December.

As we approach the end of the year, many health systems will likely be looking for opportunities for any additional cost savings after facing financial headwinds throughout 2020.